Sirolimus-eluting implant - Vascular Therapies

Drug Profile

Sirolimus-eluting implant - Vascular Therapies

Alternative Names: Coll-R

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vascular Therapies
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial disorders; Arteriovenous fistula
  • New Molecular Entity No

Highest Development Phases

  • Phase III Arteriovenous fistula
  • Clinical Phase Unknown Peripheral arterial disorders

Most Recent Events

  • 16 Nov 2017 Sirolimus-eluting implant - Vascular Therapies receives Orphan Drug status for Peripheral arterial disorders in European Union before November 2017
  • 16 Nov 2017 Efficacy data from a clinical trial in Peripheral arterial disorders released by Vascular Therapeutics (Vascular Therapeutics website, November 2017)
  • 09 Nov 2017 Efficacy data from a phase II trial in Arteriovenous fistula released by Vascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top